Faricimab treatment outcomes with extended dosing and potential for Q20W intervals in DME: post hoc analysis of the 96-week phase 3 YOSEMITE/RHINE trials

被引：0

|

作者：

Adam, Murtaza K. ^{[1
]}

Gibson, Kara ^{[2
]}

Sim, Dawn ^{[3
]}

Amador, Manuel ^{[3
]}

Hill, Lauren ^{[3
]}

Singer, Michael ^{[4
]}

机构：

[1] Colorado Retina Associates, Lakewood, CO USA

[2] Roche Prod Ltd, Welwyn Garden City, Herts, England

[3] Genentech Inc, San Francisco, CA 94080 USA

[4] Med Ctr Ophthalmol Associates, San Antonio, TX USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2024年 / 65卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

1756

引用

收藏

页数：3

相关论文

共 3 条

[1] THE POTENTIAL FOR Q20W DOSING WITH FARICIMAB AND EXTENDED TREATMENT OUTCOMES IN NAMD: A POST HOC ANALYSIS OF THE TENAYA/LUCERNE TRIALS
Patel, Praveen
Hill, Lauren
Souverain, Audrey
Kotecha, Aachal
Margaron, Philippe
EYE, 2024, 38 : 201 - 201
[2] Extended treatment outcomes and the potential for Q2OW dosing with faricimab in nAMD: a post hoc analysis of the pivotal TENAYA/LUCERNE trials
Storey, Philip
Ambresin, Aude
Koh, Adrian Hock Chaun
Singer, Michael
Hill, Lauren
Kotecha, Aachal
Margaron, Philippe
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
[3] Baseline disease characteristics in patients maintaining q12 and q16 dosing with aflibercept 8 mg versus patients with shortened treatment intervals: A Phase 3 PULSAR post hoc analysis
Lanzetta, Paolo
Leal, Sergio
Machewitz, Tobias
Zhang, Xin
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)